Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2022 | Areas of unmet need for small bowel adenocarcinoma

Karan Pandya, MD, Rutgers University, New Brunswick, NJ, highlights areas of unmet for patients with small bowel adenocarcinoma, including lack of understanding which reflects low incidence. Small bowel adenocarcinoma is often treated similarly to colorectal cancer (CRC), however, outcomes of traditional chemotherapy in small bowel adenocarcinoma is not as favourable as those seen in CRC. Additional, Dr Pandya discusses the potential of circulating tumor DNA (ctDNA) to increase understanding of small bowel adenocarcinoma disease biology. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.